Atypical Mutational Spectrum of SARS-CoV-2 Replicating in the Presence of Ribavirin

Antimicrob Agents Chemother. 2023 Jan 24;67(1):e0131522. doi: 10.1128/aac.01315-22. Epub 2023 Jan 5.

Abstract

We report that ribavirin exerts an inhibitory and mutagenic activity on SARS-CoV-2-infecting Vero cells, with a therapeutic index higher than 10. Deep sequencing analysis of the mutant spectrum of SARS-CoV-2 replicating in the absence or presence of ribavirin indicated an increase in the number of mutations, but not in deletions, and modification of diversity indices, expected from a mutagenic activity. Notably, the major mutation types enhanced by replication in the presence of ribavirin were A→G and U→C transitions, a pattern which is opposite to the dominance of G→A and C→U transitions previously described for most RNA viruses. Implications of the inhibitory activity of ribavirin, and the atypical mutational bias produced on SARS-CoV-2, for the search for synergistic anti-COVID-19 lethal mutagen combinations are discussed.

Keywords: COVID-19; SARS-CoV-2; lethal mutagenesis; ribavirin; viral quasispecies.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use
  • COVID-19*
  • Chlorocebus aethiops
  • Mutagens / pharmacology
  • Mutation
  • Ribavirin* / pharmacology
  • Ribavirin* / therapeutic use
  • SARS-CoV-2 / genetics
  • Vero Cells

Substances

  • Ribavirin
  • Antiviral Agents
  • Mutagens